{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:45Z","timestamp":1761101025218,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1440,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Outstanding Yong Scientists\u2019 Foundation of China","award":["30725038"],"award-info":[{"award-number":["30725038"]}]},{"name":"Program for Innovative Research Team in University","award":["IRT0702"],"award-info":[{"award-number":["IRT0702"]}]},{"name":"HI-Tech Research Development Program of China","award":["2006AA02Z4A0"],"award-info":[{"award-number":["2006AA02Z4A0"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.bbmt.2010.07.023","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T04:51:02Z","timestamp":1281070262000},"page":"649-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"17","author":[{"given":"Xiao-Jun","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.07.023_bib1","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1080\/10428190802322893","article-title":"OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients","volume":"49","author":"Zach","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.07.023_bib2","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.07.023_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00277-006-0196-z","article-title":"Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade","volume":"86","author":"Weisser","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2010.07.023_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.023_bib5","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.023_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.023_bib7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.023_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.10570","article-title":"Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation","volume":"92","author":"Huang","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.07.023_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s10875-008-9193-4","article-title":"Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia\u2014feasibility and safety study","volume":"28","author":"Huang","year":"2008","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.bbmt.2010.07.023_bib10","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.023_bib11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V97.6.1560","article-title":"Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"97","author":"Olavarria","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.023_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.leu.2404170","article-title":"Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"20","author":"Asnafi","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.07.023_bib13","first-page":"522","article-title":"The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse","volume":"29","author":"Xu","year":"2008","journal-title":"Chin J Hematol"},{"key":"10.1016\/j.bbmt.2010.07.023_bib14","article-title":"[Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation]","volume":"27","author":"Qin","year":"2006","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.bbmt.2010.07.023_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00277-008-0548-y","article-title":"Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up","volume":"88","author":"Qin","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2010.07.023_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1751-553X.2007.00962.x","article-title":"Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response","volume":"30","author":"Qin","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.bbmt.2010.07.023_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2010.07.023_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2010.07.023_bib19","first-page":"333","article-title":"[Efficacy and safety evaluation of imatinib in the treatment of patients with chronic granulocytic leukemia in accelerated phase]","volume":"25","author":"Jiang","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.bbmt.2010.07.023_bib20","first-page":"663","article-title":"A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation","volume":"91","author":"Weisser","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.07.023_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"author":"International Bone Marrow trans Registry","key":"10.1016\/j.bbmt.2010.07.023_bib22"},{"key":"10.1016\/j.bbmt.2010.07.023_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/sj.leu.2403425","article-title":"BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning","volume":"18","author":"Lange","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.07.023_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.bmt.1704807","article-title":"Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT)","volume":"35","author":"Michallet","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.023_bib25","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:38:48Z","timestamp":1761057528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110003241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1083879110003241"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.07.023","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}